Bristol-Myers Squibb Company
BMYLast close · Oct 16, 202659.75−0.82 (−1.35%)
Market cap$122.1B
12 firms' latest targets, last 90 days: median $65.00 ($41.00–$82.00), 9% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-12 | Jefferies | $76.00 | — | +27% |
| 2026-10-08 | Cantor Fitzgerald | $53.00 | ▼ 10% | -11% |
| 2026-10-07 | Morgan Stanley | $41.00 | ▲ 2% | -31% |
| 2026-10-05 | Leerink Partners | $59.00 | ▼ 2% | -1% |
| 2026-09-23 | Goldman Sachs | $63.00 | — | +5% |
| 2026-09-16 | Piper Sandler | $82.00 | ▲ 9% | +37% |
| 2026-09-10 | HSBC | $65.00 | ▲ 23% | +9% |
| 2026-08-05 | Roth Capital | $75.00 | — | +26% |
| 2026-08-05 | Argus Research | $75.00 | — | +26% |
| 2026-08-04 | RBC Capital | $64.00 | ▲ 7% | +7% |
| 2026-07-31 | Guggenheim | $75.00 | ▲ 4% | +26% |
| 2026-07-31 | Wells Fargo | $65.00 | ▲ 8% | +9% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $45.0B | -2% | $3.86 | +31% | est. $44.7B+1% | est. $7.38 | 16 |
| 2024reported | $48.3B | +7% | -$4.41 | -214% | est. $47.5B+2% | est. $0.92 | 17 |
| 2025reported | $48.2B | +0% | $3.46 | — | est. $48.0B+0% | est. $6.11 | 18 |
| 2026 | $49.9B | +4% | $6.32 | +3% | $49.2B–$50.2B | $5.92–$6.60 | 20 |
| 2027 | $48.5B | -3% | $6.62 | +5% | $47.4B–$49.9B | $6.11–$7.41 | 20 |
| 2028 | $41.0B | -15% | $5.41 | -18% | $38.1B–$44.5B | $4.30–$6.53 | 22 |
| 2029 | $37.7B | -8% | $4.96 | -8% | $36.6B–$38.8B | $4.77–$5.16 | 14 |
| 2030 | $37.3B | -1% | $4.98 | +0% | $36.2B–$38.5B | $4.79–$5.17 | 11 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.